MONOPRIL-HCT
LOE ApproachingNDAORALTABLET
Approved
Nov 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONOPRIL-HCT is a fixed-dose combination oral tablet combining an ACE inhibitor with a thiazide diuretic, approved in 1994 for hypertension management. The product represents a small-molecule antihypertensive combination therapy targeting patients requiring dual-agent blood pressure control. Mechanism of action involves ACE inhibition plus diuretic activity to reduce systemic vascular resistance and fluid volume.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) suggests declining team investment and shift toward generic optimization or portfolio rotation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MONOPRIL-HCT offers limited career growth given LOE approaching status and zero linked job openings; roles focus on managing transition, cost optimization, and generic competition defense rather than brand building or expansion. Career mobility is constrained to specialized generic management and operational excellence functions.
Generic Strategy ManagerSupply Chain Analyst
Worked on MONOPRIL-HCT at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.